Anonymous: "NCT01238861: A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of MED-563 in Adults with Uncontrolled Asthma", , 15 May 2013 (2013-05-15), XP055341686, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 01238861/2013_05_15 [retrieved on 2017-02-02] (B1)

Anonymous: "NCT01914757: A Multicentre, Randomized, Doubleblind, Parallel Group, Placebo-controlled, Phase III Efficacy and Safety Study of Benralizumab (MEDI-563) Added to High-dose Inhaled Corticosteroid Plus Long-acting [beta]2 Agonist in Patients With Uncontrolled Asthma (CALIMA)", , 1 August 2013 (2013-08-01), XP055341731, Retrieved from the Internet: URL:https://clinicaltrials.gov/archive/NCT 01914757/2013_08_01 [retrieved on 2017-02-02] (B1)

BUSSE W W ET AL: "Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 125, no. 6, 1 June 2010 (2010-06-01), pages 1237-1244.e2, XP027062580, ISSN: 0091-6749, DOI: 10.1016/J.JACI.2010.04.005 [retrieved on 2010-05-29] (B1)

CHUN E. JIA ET AL: "The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 131, no. 3, 1 March 2013 (2013-03-01) , pages 695-703, XP055341943, AMSTERDAM, NL ISSN: 0091-6749, DOI: 10.1016/j.jaci.2012.08.023 (B1)

GHAZI AASIA ET AL: "Benralizumab--a humanized mAb to IL-5R[alpha] with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma", EXPERT OPINION ON BIOLOGICAL THERAPY, INFORMA HEALTHCARE, UK, vol. 12, no. 1, 1 January 2012 (2012-01-01), pages 113-118, XP009159038, ISSN: 1744-7682, DOI: 10.1517/14712598.2012.642359 (B1)

JUNIPER ET AL.: 'Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire.' RESPIRATORY MEDICINE vol. 100.4, 2006, pages 616 - 621, XP005338926 (B1)

WO-A1-2008/143878 (B1)

Merck: "Asthma Severity and Control Monitoring Guide", , 1 January 2007 (2007-01-01), XP055341967, Retrieved from the Internet: URL:http://www.kyaap.org/pdf/merck-severit y_control.pdf [retrieved on 2017-02-03] (B1)

N. A. MOLFINO ET AL: "Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor", CLINICAL & EXPERIMENTAL ALLERGY, vol. 42, no. 5, 1 May 2012 (2012-05-01), pages 712-737, XP055026155, ISSN: 0954-7894, DOI: 10.1111/j.1365-2222.2011.03854.x (B1)

SANDRA R. WILSON ET AL: "Asthma outcomes: Quality of life", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 129, no. 3, 1 March 2012 (2012-03-01) , pages S88-S123, XP055341897, AMSTERDAM, NL ISSN: 0091-6749, DOI: 10.1016/j.jaci.2011.12.988 (B1)

US-A1- 2012 156 194 (B1)

US-A1- 2012 328 606 (B1)

MICHEL LAVIOLETTE ET AL: "Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 132, no. 5, 16 July 2013 (2013-07-16) , pages 1086-1096.e5, XP055277773, AMSTERDAM, NL ISSN: 0091-6749, DOI: 10.1016/j.jaci.2013.05.020 (B1)